Skip to content
OpenCapital
Get started

Spero Therapeutics, Inc. SPRO Q1 2026 earnings

Reported May 13, 2026 · After market close

Revenue$258.0KIn line
EPS-$0.13Beat by $0.05
Revenue estimate$258.0K
EPS estimate-$0.18

Next report

Aug 11, 2026 (In 1 week)
Revenue estimate$281.9K
EPS estimate-$0.17

Versus estimates

Revenue

Q1 2026$258.0KIn line
Q4 2025$41.3MBeat by $15.3MQ3 2025$3.0MMiss by $9.0MQ2 2025$11.8MBeat by $802.0KQ1 2025$5.9MMiss by $5.1MQ4 2024$9.4MBeat by $3.2M

Diluted EPS

Q1 2026-$0.13Beat by $0.05
Q4 2025$0.53Beat by $0.73Q3 2025-$0.13Beat by $0.12Q2 2025-$0.03Beat by $0.35Q1 2025-$0.25Beat by $0.30Q4 2024-$0.38Miss by $0.03

Ask the moment Spero Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Spero Therapeutics, Inc. report Q1 2026 earnings?
Spero Therapeutics, Inc. (SPRO) reported Q1 2026 earnings on May 13, 2026 after market close.
What were Spero Therapeutics, Inc.'s Q1 2026 revenue and EPS?
Spero Therapeutics, Inc. reported revenue of $258.0K and eps of $-0.13 for Q1 2026.
Did Spero Therapeutics, Inc. beat estimates in Q1 2026?
Revenue beat the consensus estimate of $258.0K by -. EPS beat the consensus estimate of $-0.18 by $0.05.
How did Spero Therapeutics, Inc.'s Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 95.6% from $5.9M a year earlier and eps grew 48.0% from $-0.25.
Where can I find Spero Therapeutics, Inc.'s Q1 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-221567) and the 10-Q periodic report (0001193125-26-221591) directly on SEC EDGAR. The filing index links above go to sec.gov.